Clinical Trials Logo

Memory Disorders clinical trials

View clinical trials related to Memory Disorders.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05831839 Enrolling by invitation - COVID-19 Clinical Trials

Computerized Training of Attention and Working Memory in Post COVID-19 Patients With Cognitive Complaints

CO-TRAINER
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

Many post COVID-19 patients suffer from cognitive deficits, even after 1 year after hospitalization. These complaints have a huge impact on psychological well-being and quality of life. In rehabilitation programs in the Netherlands, most interventions are based on physical therapy or learning how to cope with fatigue and low levels of energy. In former studies computerized training of cognition in other populations has been proven to be effective. Knowledge on the effect of computerized training on attention and working memory in patients suffering from COVID-19 is urgently needed, and may contribute to more evidence-based rehabilitation programs for these patients. Therefore the effectiveness of computerized training of attention and working memory in post COVID-19 patients with cognitive complaints will be studied in this study.

NCT ID: NCT04701177 Enrolling by invitation - Alzheimer Disease Clinical Trials

Digitally-enhanced, Decentralized, Multi-omics Observational Cohort

ANANEOS
Start date: March 15, 2021
Phase:
Study type: Observational [Patient Registry]

The study is carried out as part of the GR2021 Priority project "Healthy Brains for life (Age 20-99): Digitally-enhanced personalized medicine study ANANEOS" and code numbered GR-00546 and it will look at the decentralized and remote assessment of the symptoms of preclinical stages in Alzheimer's disease and movement disorders, e.g. Parkinson's. For this study we are looking for participants aged over 45 without cognitive complaints or with subjective perception of cognitive decline or with mild cognitive complaints. Specific aims for the proposed study: a) to develop novel sensitive measures that can provide an early identification of those SCD and MCI individuals harboring AD pathology that are at high risk of cognitive worsening over time; b) to track pre-motor stages in Parkinson's disease and trials that enable active digital functional biomarkers; c) to track disease progression during pre-dementia and pre-motor stages in clinical practice and trials with measures that enable to capture subtle changes.